secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beyond Air, Inc. (XAIR)
CIK:        0001641631
Form:       8-K
Filed at:   2026-08-18T20:30:32+00:00
Accession:  0001493152-26-039020
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beyond Air Q1 revenue $1.8M flat YoY, net loss $7.9M; raises $30.1M financing, reaffirms CY2026 guidance
--------------------------------------------------------------------------------

- Revenue $1.8M flat YoY; gross margin improved to 13% from 9%.
- Net loss $7.9M ($11.00/share) vs $7.7M ($30.67/share) prior year.
- Cash $15.2M at June 30; subsequent up to $30.1M financing ($10.2M upfront, $20M warrants, $10M tied to FDA approval).
- Reaffirms CY2026 revenue guidance $8M; CY2027 $16-18M (110%+ growth).
- PMA supplement for 2nd-gen LungFit PH under FDA review; approval expected 2H CY2026; GPO deal adds ~2,000 hospitals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641631/000149315226039020/0001493152-26-039020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641631/000149315226039020/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-039020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer